Ontology highlight
ABSTRACT: Background
Proprotein convertase subtilisin/kexin type 9 inhibitors, such as evolocumab, are cholesterol-lowering drugs effective in lowering lipid levels in high-risk patients with primary hypercholesterolemia or mixed dyslipidemia.Objective
This study assessed the cost effectiveness of evolocumab in combination with lipid-lowering therapies (LLTs) compared with LLTs alone, from a public healthcare perspective in the Kingdom of Saudi Arabia (KSA).Methods
A Markov cohort state transition model was used, incorporating efficacy estimates from the FOURIER clinical trial and baseline cardiovascular event rates observed in clinical practice. Other model inputs were extracted from the literature and Saudi sources.Results
In patients with clinically evident atheros
SUBMITTER: Alghamdi A
PROVIDER: S-EPMC8864041 | biostudies-literature | 2022 Mar
REPOSITORIES: biostudies-literature